190 related articles for article (PubMed ID: 37326412)
1. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway.
Xie W; Li S; Guo H; Zhang J; Tu M; Wang R; Lin B; Wu Y; Wang X
Cancer Med; 2023 Jul; 12(14):15317-15336. PubMed ID: 37326412
[TBL] [Abstract][Full Text] [Related]
2. Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Kawahara T; Aljarah AK; Shareef HK; Inoue S; Ide H; Patterson JD; Kashiwagi E; Han B; Li Y; Zheng Y; Miyamoto H
Prostate; 2016 Jun; 76(8):744-56. PubMed ID: 26864615
[TBL] [Abstract][Full Text] [Related]
3. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth.
Rosati R; Patki M; Chari V; Dakshnamurthy S; McFall T; Saxton J; Kidder BL; Shaw PE; Ratnam M
J Biol Chem; 2016 Dec; 291(50):25983-25998. PubMed ID: 27793987
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.
Urbanucci A; Sahu B; Seppälä J; Larjo A; Latonen LM; Waltering KK; Tammela TL; Vessella RL; Lähdesmäki H; Jänne OA; Visakorpi T
Oncogene; 2012 Apr; 31(17):2153-63. PubMed ID: 21909140
[TBL] [Abstract][Full Text] [Related]
5. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.
Patki M; Chari V; Sivakumaran S; Gonit M; Trumbly R; Ratnam M
J Biol Chem; 2013 Apr; 288(16):11047-65. PubMed ID: 23426362
[TBL] [Abstract][Full Text] [Related]
6. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
8. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FEN1 promotes DNA damage and enhances chemotherapeutic response in prostate cancer cells.
Wang Z; Yong C; Fu Y; Sun Y; Guo Z; Liu SB; Hu Z
Med Oncol; 2023 Jul; 40(8):242. PubMed ID: 37452976
[TBL] [Abstract][Full Text] [Related]
10. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
13. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
[TBL] [Abstract][Full Text] [Related]
15. Identification of ELK1 interacting peptide segments in the androgen receptor.
Soave C; Ducker C; Kim S; Strahl T; Rosati R; Huang Y; Shaw PE; Ratnam M
Biochem J; 2022 Jul; 479(14):1519-1531. PubMed ID: 35781489
[TBL] [Abstract][Full Text] [Related]
16. Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.
Wang Y; Li S; Zhu L; Zou J; Jiang X; Chen M; Chen B
Clin Transl Oncol; 2019 Aug; 21(8):1026-1033. PubMed ID: 30712236
[TBL] [Abstract][Full Text] [Related]
17. Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation.
Sen A; De Castro I; Defranco DB; Deng FM; Melamed J; Kapur P; Raj GV; Rossi R; Hammes SR
J Clin Invest; 2012 Jul; 122(7):2469-81. PubMed ID: 22684108
[TBL] [Abstract][Full Text] [Related]
18. CA916798 affects growth and metastasis of androgen-dependent prostate cancer cells.
He J; Lan X; Duan HL; Luo H; Zhou XD
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4477-4487. PubMed ID: 30058677
[TBL] [Abstract][Full Text] [Related]
19. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
[TBL] [Abstract][Full Text] [Related]
20. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
Bennett NC; Hooper JD; Johnson DW; Gobe GC
Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
